Skip to main content

Allogene Therapeutics, Inc.

ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001737287

In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.

13F holders, Q1 2025

Institutional positions in Allogene Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
171
−1 vs. Q4 2024
Shares held
197.1M
+8.97M (+4.8%) vs. Q4 2024
Total value
$288.5M
−$112.3M (−28.0%) vs. Q4 2024
New holders
28
64 more added
Sold out
29
41 more reduced

2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting ALLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2025: 171 institutions
Q1 2021: 169 institutionsQ2 2021: 182 institutionsQ3 2021: 169 institutionsQ4 2021: 177 institutionsQ1 2022: 180 institutionsQ2 2022: 161 institutionsQ3 2022: 192 institutionsQ4 2022: 168 institutionsQ1 2023: 176 institutionsQ2 2023: 171 institutionsQ3 2023: 155 institutionsQ4 2023: 170 institutionsQ1 2024: 161 institutionsQ2 2024: 175 institutionsQ3 2024: 156 institutionsQ4 2024: 174 institutionsQ1 2025: 171 institutionsQ2 2025: 158 institutionsQ3 2025: 170 institutionsQ4 2025: 172 institutionsQ1 2026: 209 institutionsQ2 2026: 209 institutions
Value heldQ1 2025: $288.5M
Q1 2021: $3.12BQ2 2021: $2.25BQ3 2021: $2.26BQ4 2021: $1.28BQ1 2022: $836.7MQ2 2022: $1.15BQ3 2022: $1.15BQ4 2022: $700.9MQ1 2023: $582.3MQ2 2023: $662.9MQ3 2023: $413.3MQ4 2023: $392.4MQ1 2024: $586.0MQ2 2024: $385.1MQ3 2024: $460.4MQ4 2024: $401.9MQ1 2025: $288.5MQ2 2025: $207.9MQ3 2025: $201.0MQ4 2025: $222.7MQ1 2026: $444.7MQ2 2026: $652.0M
Institutions holding ALLO and their total value by quarter
QuarterHoldersValue
Q2 2026209$652.0M
Q1 2026209$444.7M
Q4 2025172$222.7M
Q3 2025170$201.0M
Q2 2025158$207.9M
Q1 2025171$288.5M
Q4 2024174$401.9M
Q3 2024156$460.4M
Q2 2024175$385.1M
Q1 2024161$586.0M
Q4 2023170$392.4M
Q3 2023155$413.3M
Q2 2023171$662.9M
Q1 2023176$582.3M
Q4 2022168$700.9M
Q3 2022192$1.15B
Q2 2022161$1.15B
Q1 2022180$836.7M
Q4 2021177$1.28B
Q3 2021169$2.26B
Q2 2021182$2.25B
Q1 2021169$3.12B

Institutions, Q1 2025

Shares, value and share of portfolio for each institution holding Allogene Therapeutics, Inc.; share changes are against Q4 2024.

Institutions holding ALLO in Q1 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Nuveen Asset Management, LLC––––Not filed
Caxton Associates LP––––Not filed